Concentrating management resources on recombinant human HGF protein
First written in FY2020. 11 of 12 entries say "Restated". Latest entry: 2026-05-18.
No other company in this theme has enough history to compare yet.
- 2026-05-18RestatedFinancial results presentation
「当社は、当面は優先順位として急性期での HGF タンパク質単剤の開発を軸に据えながら、中長期的な成長機会として慢性期領域の開発可能性を追求していく方針です。」
当面は脊髄損傷急性期のHGFタンパク質単剤開発を優先する方針を明示した。 - FY2025-H1RestatedAnnual report
「Against this backdrop, we believe that creating drug discovery innovation through the research and development of recombinant human HGF protein (development code: KP-100) will lead to the creation and capture of business opportunities. We therefore concentrated management resources on the recombinant human HGF protein project and conducted the following business activities.」
The company continues to treat the research and development of KP-100 and the concentration of management resources on the project as the foundation of its business activities. - FY2024-Q2RestatedAnnual report
「Against this backdrop, we believe that creating drug discovery innovation through the research and development of recombinant human HGF protein (development code: KP-100) will lead to the creation and capture of business opportunities. We therefore concentrated management resources on the recombinant human HGF protein project and conducted the following business activities.」
The company continues to treat the research and development of KP-100 and the concentration of management resources on the project as the basis of its business activities. - FY2024-Q1RestatedAnnual report
「Against this backdrop, we believe that creating drug discovery innovation through the research and development of recombinant human HGF protein (development code: KP-100) will lead to the creation and capture of business opportunities. We therefore concentrated management resources on the recombinant human HGF protein project and conducted the following business activities.」
The company continues to treat the research and development of KP-100 and the concentration of management resources on the project as the basis of its business activities. - FY2023-Q3RestatedAnnual report
「Against this backdrop, we believe that creating drug discovery innovation through the research and development of recombinant human HGF protein (development code: KP-100) will lead to the creation and capture of business opportunities. We therefore concentrated management resources on the recombinant human HGF protein project and conducted the following business activities.」
The company continues to treat drug discovery innovation through the research and development of KP-100 and the concentration of management resources on the project as the basis of its business activities. - FY2023-Q2RestatedAnnual report
「Against this backdrop, we believe that creating drug discovery innovation through the research and development of recombinant human HGF protein (development code: KP-100) will lead to the creation and capture of business opportunities. We therefore concentrated management resources on the recombinant human HGF protein project and conducted the following business activities.」
The company continues to treat the research and development of KP-100 and the concentration of management resources on the project as the basis of its business activities. - FY2023-Q1RestatedAnnual report
「Against this backdrop, we believe that creating drug discovery innovation through the research and development of recombinant human HGF protein (development code: KP-100) will lead to the creation and capture of business opportunities. We therefore concentrated management resources on the recombinant human HGF protein project and conducted the following business activities.」
The company continues to treat drug discovery innovation through the research and development of KP-100 and the concentration of management resources on the project as the basis of its business activities. - FY2022RestatedAnnual report
「We believe that creating drug discovery innovation through the research and development of recombinant human HGF protein will lead to the creation and capture of business opportunities. We are therefore concentrating management resources on the recombinant human HGF protein project and developing our business accordingly.」
The company continues to make the concentration of management resources on the recombinant human HGF protein project the foundation of its business development. - FY2022-Q3RestatedAnnual report
「Against this backdrop, we believe that creating drug discovery innovation through the research and development of recombinant human HGF protein (development code: KP-100) will lead to the creation and capture of business opportunities. We therefore concentrated management resources on the recombinant human HGF protein project and conducted the following business activities.」
The company continues to treat the concentration of management resources on the recombinant human HGF protein project as the basis of its business activities. - FY2022-Q2RestatedAnnual report
「Against this backdrop, we believe that creating drug discovery innovation through the research and development of recombinant human HGF protein will lead to the creation and capture of business opportunities. We therefore concentrated management resources on the recombinant human HGF protein project and conducted the following business activities.」
The company continues to treat the concentration of management resources on the recombinant human HGF protein project as the basis of its business activities. - FY2022-Q1RestatedAnnual report
「Against this backdrop, we believe that creating drug discovery innovation through the research and development of recombinant human HGF protein will lead to the creation and capture of business opportunities. We therefore concentrated management resources on the recombinant human HGF protein project and conducted the following business activities.」
The company continues to treat the concentration of management resources on the recombinant human HGF protein project as the basis of its business activities. - FY2020First statedAnnual report
「We are concentrating management resources on the recombinant human HGF protein project and developing our business accordingly.」
The company is developing its business around recombinant human HGF protein as its sole drug discovery seed.